BlackRock Group’s Protalix BioTherapeutics PLX Stock Holding History

BlackRock Group’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$48K	Hold	10,870	–	–	﹤0.01%	2917
2016 Q3	$62K	Hold	10,870	–	–	﹤0.01%	2886
2016 Q2	$70K	Hold	10,870	–	–	﹤0.01%	2858
2016 Q1	$91K	Hold	10,870	–	–	﹤0.01%	2793
2015 Q4	$111K	Hold	10,870	–	–	﹤0.01%	2664
2015 Q3	$128K	Hold	10,870	–	–	﹤0.01%	2648
2015 Q2	$212K	Sell	10,870 -44,207	-80%	-$917K	﹤0.01%	2563
2015 Q1	$980K	Hold	55,077	–	–	﹤0.01%	1879
2014 Q4	$1.01M	Hold	55,077	–	–	﹤0.01%	1861
2014 Q3	$1.33M	Buy	55,077 +11,320	+26%	+$326K	﹤0.01%	1617
2014 Q2	$1.6M	Hold	43,757	–	–	﹤0.01%	1582
2014 Q1	$2M	Hold	43,757	–	–	﹤0.01%	1570
2013 Q4	$1.7M	Hold	43,757	–	–	﹤0.01%	1636
2013 Q3	$1.98M	Buy	43,757 +16,090	+58%	+$826K	﹤0.01%	1475
2013 Q2	$1.36M	Buy	+27,667	New	+$1.47M	﹤0.01%	1526

Other funds holding PLX

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AGC

Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BlackRock Group's PLX Position: Q4 2016 in Review

BlackRock Group held its Protalix BioTherapeutics (PLX) position steady in Q4 2016 at 10,870 shares worth $48K. The position accounts for ﹤0.01% of the portfolio, ranked #2917.

BlackRock Group first reported a position in PLX in Q2 2013 and has held it in 15 quarters since. The position peaked at $2M in Q1 2014. 33 funds tracked by Wall St. Rank hold PLX as of Q4 2016.

BlackRock Group held 10,870 shares of Protalix BioTherapeutics worth $48K as of Q4 2016.
BlackRock Group left its Protalix BioTherapeutics share count unchanged in Q4 2016.
Protalix BioTherapeutics made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2917 holding.
BlackRock Group first reported a position in Protalix BioTherapeutics in Q2 2013 and has held it in 15 quarters since.
BlackRock Group's Protalix BioTherapeutics position peaked at $2M in Q1 2014.
33 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.